IL286929A - חלבונים קושרים שלושה-ספציפיים, שיטות, ושימוש שלהם - Google Patents
חלבונים קושרים שלושה-ספציפיים, שיטות, ושימוש שלהםInfo
- Publication number
- IL286929A IL286929A IL286929A IL28692921A IL286929A IL 286929 A IL286929 A IL 286929A IL 286929 A IL286929 A IL 286929A IL 28692921 A IL28692921 A IL 28692921A IL 286929 A IL286929 A IL 286929A
- Authority
- IL
- Israel
- Prior art keywords
- methods
- binding proteins
- trispecific binding
- trispecific
- proteins
- Prior art date
Links
- 102000014914 Carrier Proteins Human genes 0.000 title 1
- 108091008324 binding proteins Proteins 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464402—Receptors, cell surface antigens or cell surface determinants
- A61K39/464403—Receptors for growth factors
- A61K39/464406—Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ ErbB4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464402—Receptors, cell surface antigens or cell surface determinants
- A61K39/464429—Molecules with a "CD" designation not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Oncology (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Peptides Or Proteins (AREA)
- Engineering & Computer Science (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Biomedical Technology (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Hematology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962831572P | 2019-04-09 | 2019-04-09 | |
EP19306261 | 2019-10-02 | ||
PCT/US2020/027320 WO2020210392A1 (en) | 2019-04-09 | 2020-04-08 | Trispecific binding proteins, methods, and uses thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
IL286929A true IL286929A (he) | 2021-10-31 |
Family
ID=72751423
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IL286929A IL286929A (he) | 2019-04-09 | 2021-10-03 | חלבונים קושרים שלושה-ספציפיים, שיטות, ושימוש שלהם |
Country Status (13)
Country | Link |
---|---|
EP (1) | EP3953388A1 (he) |
JP (1) | JP2022527994A (he) |
KR (1) | KR20210149141A (he) |
CN (1) | CN113950484A (he) |
AU (1) | AU2020272839A1 (he) |
BR (1) | BR112021019915A2 (he) |
CA (1) | CA3136821A1 (he) |
CO (1) | CO2021014918A2 (he) |
IL (1) | IL286929A (he) |
MX (1) | MX2021012386A (he) |
SG (1) | SG11202111012QA (he) |
TW (1) | TW202104261A (he) |
WO (1) | WO2020210392A1 (he) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2020076853A1 (en) * | 2018-10-09 | 2020-04-16 | Sanofi | Trispecific anti-cd38, anti-cd28, and anti-cd3 binding proteins and methods of use for treating viral infection |
TW202104274A (zh) * | 2019-04-09 | 2021-02-01 | 法商賽諾菲公司 | 用於治療hiv感染之三特異性及/或三價結合蛋白 |
WO2024077118A2 (en) * | 2022-10-06 | 2024-04-11 | Bicara Therapeutics Inc. | Multispecific proteins and related methods |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9200061B2 (en) * | 2004-02-06 | 2015-12-01 | Morpho Sys AG | Generation and profiling of fully human HuCAL gold®-derived therapeutic antibodies specific for human CD3i |
JOP20210044A1 (ar) * | 2010-12-30 | 2017-06-16 | Takeda Pharmaceuticals Co | الأجسام المضادة لـ cd38 |
TWI671315B (zh) * | 2011-03-28 | 2019-09-11 | 法商賽諾菲公司 | 具有交叉結合區定向之雙重可變區類抗體結合蛋白 |
ES2808914T3 (es) * | 2014-09-04 | 2021-03-02 | Stemcell Tech Inc | Complejos de anticuerpo solubles para la activación y expansión de linfocitos T o células NK |
ES2808853T3 (es) * | 2014-11-20 | 2021-03-02 | Hoffmann La Roche | Cadenas ligeras comunes y procedimientos de uso |
JP7146395B2 (ja) * | 2014-11-20 | 2022-10-04 | エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト | FolR1及びCD3を標的とする二重特異性抗体 |
TWI726862B (zh) * | 2015-01-23 | 2021-05-11 | 法商賽諾菲公司 | 特異性結合cd3及/或cd123之抗-cd3抗體,抗-cd123抗體及雙特異性抗體 |
CA2986592A1 (en) * | 2015-06-17 | 2016-12-22 | Genentech, Inc. | Anti-her2 antibodies and methods of use |
US20180142010A1 (en) * | 2015-06-26 | 2018-05-24 | Alexion Pharmaceuticals, Inc. | Method for treating a patient in compliance with vaccination with eculizumab or an eculizumab variant |
CN117069855A (zh) | 2015-10-25 | 2023-11-17 | 赛诺菲 | 用于预防或治疗hiv感染的三特异性和/或三价结合蛋白 |
KR20180134378A (ko) | 2016-04-13 | 2018-12-18 | 사노피 | 3특이성 및/또는 3가 결합 단백질 |
JP2019532017A (ja) * | 2016-07-14 | 2019-11-07 | フレッド ハッチンソン キャンサー リサーチ センター | がんを治療するための異なるエピトープ結合を示す複数の二重特異性結合ドメイン構築物 |
EP3575319A4 (en) * | 2016-12-30 | 2021-03-10 | Shanghai Sinobio Biotech Co., Ltd. | BIFUNCTIONAL MOLECULE AND USE OF IT |
CA3078800A1 (en) * | 2017-10-10 | 2019-04-18 | Sanofi | Anti-cd38 antibodies and methods of use |
WO2020076853A1 (en) * | 2018-10-09 | 2020-04-16 | Sanofi | Trispecific anti-cd38, anti-cd28, and anti-cd3 binding proteins and methods of use for treating viral infection |
-
2020
- 2020-04-08 AU AU2020272839A patent/AU2020272839A1/en active Pending
- 2020-04-08 BR BR112021019915A patent/BR112021019915A2/pt unknown
- 2020-04-08 JP JP2021559759A patent/JP2022527994A/ja active Pending
- 2020-04-08 MX MX2021012386A patent/MX2021012386A/es unknown
- 2020-04-08 CN CN202080041550.1A patent/CN113950484A/zh active Pending
- 2020-04-08 KR KR1020217036094A patent/KR20210149141A/ko unknown
- 2020-04-08 TW TW109111809A patent/TW202104261A/zh unknown
- 2020-04-08 CA CA3136821A patent/CA3136821A1/en active Pending
- 2020-04-08 SG SG11202111012QA patent/SG11202111012QA/en unknown
- 2020-04-08 EP EP20722422.1A patent/EP3953388A1/en active Pending
- 2020-04-08 WO PCT/US2020/027320 patent/WO2020210392A1/en unknown
-
2021
- 2021-10-03 IL IL286929A patent/IL286929A/he unknown
- 2021-11-04 CO CONC2021/0014918A patent/CO2021014918A2/es unknown
Also Published As
Publication number | Publication date |
---|---|
KR20210149141A (ko) | 2021-12-08 |
JP2022527994A (ja) | 2022-06-07 |
EP3953388A1 (en) | 2022-02-16 |
WO2020210392A1 (en) | 2020-10-15 |
AU2020272839A1 (en) | 2021-12-02 |
SG11202111012QA (en) | 2021-11-29 |
BR112021019915A2 (pt) | 2021-12-07 |
TW202104261A (zh) | 2021-02-01 |
MX2021012386A (es) | 2022-01-18 |
CO2021014918A2 (es) | 2021-11-19 |
CN113950484A (zh) | 2022-01-18 |
CA3136821A1 (en) | 2020-10-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL277398A (he) | אפימרים קושרים pd-l1 ושימושים קשורים להם | |
PT3443006T (pt) | Proteínas de ligação triespecíficas e/ou trivalentes | |
IL278943A (he) | חלבונים קושרים רבי-ספציפיות ושיפורים בהם | |
EP3452089A4 (en) | BISPECIFIC BINDING PROTEINS AND USES THEREOF | |
ZA201901592B (en) | Recombinant binding proteins and their use | |
EP3655432A4 (en) | BINDING PROTEIN 1 | |
IL272553A (he) | חלבונים אשר קושרים d2nkg, 16cd, ו- egfr, e-hla, 4ccr, או 1l-pd | |
IL268567A (he) | חלבונים קושרי bcma, nkg2d ו- cd16 | |
IL268755A (he) | חלבונים הקושרים her2, nkg2d, ו- cd16 | |
EP3613771A4 (en) | FOR LRIG-1 PROTEIN SPECIFIC BINDING MOLECULE AND USE OF IT | |
IL286929A (he) | חלבונים קושרים שלושה-ספציפיים, שיטות, ושימוש שלהם | |
EP3689893A4 (en) | IMMUNOGLOBULIN-BINDING PROTEIN AND AFFINITY CARRIERS THEREFORE | |
IL284664A (he) | חלבונים קושרים מולטיספציפיים | |
EP3515948A4 (en) | COAGULATION FACTOR BINDING PROTEINS AND USES THEREOF | |
EP3380514A4 (en) | GDF131-BINDING PROTEINS AND USES THEREOF | |
ZA202103259B (en) | Modified cas9 protein, and use thereof | |
EP3705121A4 (en) | EMOPAMIL BINDING PROTEIN BINDING AGENT AND ITS USE | |
EP3689894A4 (en) | IMMUNOGLOBULIN-BINDING PROTEIN AND AFFINITY CARRIERS THEREFORE | |
EP3882266A4 (en) | LRIG-1 PROTEIN SPECIFIC BINDING MOLECULE AND USE THEREOF | |
IL289145A (he) | חלבונים קושרים il1rap | |
IL304317A (he) | חלבונים קושרי tgf–beta–rii | |
EP3700571A4 (en) | ALK7-BINDING PROTEINS AND USES THEREOF | |
IL284317A (he) | חלבוני פסאודו fab קושרים מולטיספציפיים | |
EP4077385A4 (en) | CXCL10-BINDING PROTEINS AND USES THEREOF | |
EP3973550C0 (en) | PEPTIDE IONOGEL, COMPOSITION, METHODS AND USES THEREOF |